Pall opens Center of Excellence in Shanghai

19 Dec 2018

The CoE showcases the latest end-to-end technological solutions for biomanufacturing.

Pall Corporation has established a Biotech Integrated Solutions Center of Excellence (CoE) in Shanghai, China. Strategically located in the heart of Shanghai’s renowned life science cluster, the CoE is a new state-of-the-art facility for bioprocess engineering consultancy, technology demonstration, testing and training for China and broader Asia.

Pall opens Center of Excellence in Shanghai

Equipped with advanced bioprocessing equipment and automation platforms, the CoE showcases the latest end-to-end technological solutions for biomanufacturing, including single-use cell culture solutions, cell clarification using acoustic wave technology, chromatography using automated packing techniques, viral clearance, tangential flow filtration and mixer/container modules. It is designed to lead Pall’s customers through the sequential stages of process flow and will serve as a proving ground for new technologies, as well as a training facility for Pall customers and Pall employees.

“As the biopharmaceutical industry moves from traditional batch or single-use processing to continuous bioprocessing solutions, Pall is poised to help customers reduce process development and production costs and drive significant improvements in efficacy and productivity,” President of Pall Corporation, Jennifer Honeycutt, explained.

“Our investment in the new Shanghai CoE is designed to give Pall customers options ranging from batch to single use and continuous bioprocessing solutions, depending upon where customers are in their journey. The goal is to provide technology solutions that meet their current needs, while offering some of the most progressive technological solutions for the future,” added Honeycutt. “By opening this state-of-the-art facility, we hope to unlock new opportunities for our customers based in China, and for any global customers looking to enter or expand their operations in the Asia Pacific region.”

Pall Biotech has invested heavily in a growing network of CoE facilities worldwide to support its global biopharmaceutical customer base. Three CoE facilities currently exist in Portsmouth (UK), Westborough (USA), and Shanghai (China), with planning for a new European facility in process.

Read More

Related news

Can the industry really claim it's 'business as usual'?

Can the industry really claim it's 'business as usual'?

19 May 2020

ChargePoint Technology's Chief Commercial Officer says "yes" it can.

Read more 
HKBU scientists develop technique to eliminate drug side effects

HKBU scientists develop technique to eliminate drug side effects

19 May 2020

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

Read more 
Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

19 May 2020

The certification is expected to instill greater 'supply' trust with clients, particularly during the current pandemic.

Read more 
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

18 May 2020

CDMO is contracted to produce multiple clinical batches from German facility

Read more 
Pharmapack expert recommends holistic approach to sustainability

Pharmapack expert recommends holistic approach to sustainability

18 May 2020

Although the industry might be 30% along its sustainability journey, greater interoperability is needed from materials to devices.

Read more 
KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

12 May 2020

Company's manufacturing methods and processes reviewed by an independent third-party auditor to ensure the products have the highest-quality ingredients possible.

Read more 
Characterizing virus and virus-like particles

Characterizing virus and virus-like particles

12 May 2020

New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

Read more 
Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

12 May 2020

CDMO says it has made "notable changes" to its supply chain processes to ensure continuing supply of medicines during COVID-19 pandemic

Read more 
AI technology company launches with Novartis and Sarepta deals

AI technology company launches with Novartis and Sarepta deals

11 May 2020

Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

Read more 
Demand for immunity products to be sustained long-term says SIRIO

Demand for immunity products to be sustained long-term says SIRIO

11 May 2020

Movement towards healthy lifestyles and preventative supplements the lasting behavioural change post COVID-19.

Read more